Christopher Liu
Stock Analyst at Leerink Partners
(3.00)
# 1,326
Out of 5,124 analysts
9
Total ratings
83.33%
Success rate
59.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Upgrades: Outperform | $48 | $43.83 | +9.51% | 2 | Oct 21, 2025 | |
| LYEL Lyell Immunopharma | Initiates: Buy | $20 | $30.78 | -35.02% | 1 | Sep 26, 2025 | |
| ADAG Adagene | Initiates: Buy | $9 | $1.89 | +376.19% | 1 | Sep 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $10 | $4.36 | +129.36% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $8.46 | +112.77% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $34.57 | -21.90% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $100.59 | -58.25% | 1 | Aug 8, 2023 |
Exelixis
Oct 21, 2025
Upgrades: Outperform
Price Target: $48
Current: $43.83
Upside: +9.51%
Lyell Immunopharma
Sep 26, 2025
Initiates: Buy
Price Target: $20
Current: $30.78
Upside: -35.02%
Adagene
Sep 18, 2025
Initiates: Buy
Price Target: $9
Current: $1.89
Upside: +376.19%
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $4.36
Upside: +129.36%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $8.46
Upside: +112.77%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $34.57
Upside: -21.90%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $100.59
Upside: -58.25%